

“What’s New” Medical Pharmaceutical Policy November 2020 Updates

MBP 29.0 Elitek (rasburicase)- Updated policy

- Physician provided documentation verifies a diagnosis of lymphoma, leukemia or solid tumor malignancies; **AND**
- Physician provided documentation of high risk for tumor lysis syndrome characterized by the presence of **ONE of the following “high risk” factors:**
 - Renal disease or renal involvement by **tumor** ~~Elevated serum creatinine;~~ **or**
 - ~~Leukemias with very high white blood cell counts of greater than or equal to 25,000/mm³;~~
 - ~~or~~
 - ~~Burkitt’s lymphoma;~~ **or**
 - ~~T-cell non-Hodgkin’s lymphoma;~~ **or**
 - Serum uric acid level greater than or equal to 8 mg/dL
 - **Spontaneous Tumor Lysis Syndrome (TLS)**
 - **Elevated White Blood Cell (WBC) count greater than 50 x 10⁹/L**
 - **Bone Marrow involvement**
 - Diagnosis of any of the following:
 - Burkitt’s lymphoma **or Burkitt’s Leukemia**
 - Lymphoblastic lymphoma
 - T-cell Non-Hodgkin’s lymphoma
 - **Plasma cell leukemia**
 - **Chronic lymphocytic leukemia (CLL) treated with venetoclax and lymph node ≥10 cm, or lymph node ≥5 cm and absolute lymphocyte count ≥25 x 10⁹/L and elevated baseline uric acid.**
 - **Acute lymphoblastic leukemia (ALL) with WBC greater than or equal to 100 x 10⁹/L and/or serum lactate dehydrogenase (LDH) greater than or equal to two times the upper limit of normal**
 - **acute myeloid leukemia (AML) with WBC greater than or equal to 100 x 10⁹/L**
 - **Adult T cell leukemia/lymphoma, diffuse large B-cell, transformed, and mantle cell lymphomas with serum LDH level above the upper limit of normal with a bulky tumor mass, or myeloma with extra medullary disease**
 - **Stage III/IV childhood diffuse large B-cell lymphoma with LDH ≥2 x ULN**

AND- OR

- Physician provided documentation of therapeutic failure on, intolerance to, or contraindication to oral or injectable allopurinol

The following policies were reviewed with no changes:

- MBP 159.0 Kymriah (tisagenlecleucel)
- MBP 162.0 Yescarta (axicabtagene ciloleucel)
- MBP 170.0 Lutathera (lutetium Lu 177 dotatate)
- MBP 24.0 Aloxi (palonosetron)
- MBP 42.0 Boniva IV (ibandronate)
- MBP 49.0 Erythropoietin and Darbepoetin Therapy
- MBP 57.0 Tysabri (natalizumab)
- MBP 81.0 Prolia (denosumab)
- MBP 104.0 Emend IV (fosaprepitant)
- MBP 130.0 Mircera (methoxy polyethylene glycol-epoetin beta)
- MBP 141.0 Nucala vial (mepolizumab)
- MBP 150.0 Sustol (granisetron ER)
- MBP 155.0 Ocrevus (ocrelizumab)
- MBP 173.0 Fasentra Prefilled Syringe (benralizumab)
- MBP 204.0 Triptodur (triptorelin)